CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-25 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Grant or award | +120,000 | 833,405 | ||
| 2025-02-25 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (Right to Buy) | +560,000 | 560,000 | ||
| 2025-02-25 | Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY | Shares withheld for taxes | −1,375 | $0.96 | $1K | 694,842 |
| 2025-02-25 | Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY | Grant or award | +120,000 | 814,842 | ||
| 2025-02-25 | Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY | Grant or award · Stock Option (Right to Buy) | +560,000 | 560,000 | ||
| 2025-02-25 | Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −1,375 | $0.96 | $1K | 691,803 |
| 2025-02-25 | Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER | Grant or award | +120,000 | 811,803 | ||
| 2025-02-25 | Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +560,000 | 560,000 | ||
| 2025-02-25 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Shares withheld for taxes | −10,663 | $0.96 | $10K | 2,077,848 |
| 2025-02-25 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Grant or award | +375,000 | 2,452,848 | ||
| 2025-02-25 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Grant or award · Stock Option (Right to Buy) | +1,750,000 | 1,750,000 | ||
| 2025-02-24 | Davis Gregory D Head of Research & Technology | Shares withheld for taxes | −705 | $1.00 | $705 | 166,865 |
| 2025-02-24 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Shares withheld for taxes | −1,792 | $1.00 | $2K | 714,918 |
| 2025-02-24 | Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY | Shares withheld for taxes | −1,434 | $1.00 | $1K | 696,217 |
| 2025-02-24 | Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −1,792 | $1.00 | $2K | 693,178 |
| 2025-02-24 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Shares withheld for taxes | −7,488 | $1.00 | $7K | 2,088,511 |
| 2025-01-22 | Davis Gregory D Head of Research & Technology | Shares withheld for taxes | −30,456 | $1.15 | $35K | 167,570 |
| 2025-01-22 | Willoughby Scott B. SVP, GEN. COUNSEL & SECRETARY | Shares withheld for taxes | −129,549 | $1.15 | $149K | 697,651 |
| 2025-01-22 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Shares withheld for taxes | −129,593 | $1.15 | $149K | 716,710 |
| 2025-01-22 | Duraibabu Prathyusha SVP, CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −129,242 | $1.15 | $149K | 694,970 |
Page 5 of 9 · 165 trades